지에프씨생명과학

388610KOSDAQ

44.0 / 100

Reference Date: 2026-10-23

Financial Score14.5 / 40

News Sentiment12.5 / 25

Momentum7.0 / 20

Disclosure10.0 / 15

AI Analysis: the debt ratio is very low with excellent financial health but PER raises overvaluation concerns. Plunged 17.2% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

GFCC Life Sciences operates two main business units: the Material Business Unit, which develops innovative cosmetic ingredients using skin microbiome and exosome technologies, and the Clinical Business Unit, which provides human efficacy testing services for cosmetics. The Material Business Unit leverages a library of over 2,000 strains and proprietary patents to produce high-value raw materials, expanding into the growing skin booster market. The Clinical Business Unit benefits from increased demand for efficacy verification due to regulatory changes, driving sustained revenue growth.

Number of Employees

86people

Average Salary

47.9M KRW

Score Calculation Basis

Detailed Financial Score

PER

40.87Industry Average 15.000.0Point

2.7x industry avg (risky)

PBR

1.05Industry Average 1.204.0Point

In line with industry avg

ROE

3.20Industry Average 8.001.0Point

Well below industry avg

Debt Ratio

33.67Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2024~20253.0 / 10 points

Revenue Growth Rate

2.0 / 3

Avg ▲5.4% (1-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼77.3% (1-year basis)

ROE Trend

1.0 / 4

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 4,700Won52-week high 18,60052-week low 4,600

1-month return0.0Point

1m -17.25% (strong drop)

Volume trend6.0Point

Volume surge

Detailed Disclosure

6 totalPositive 0Neutral 6Negative 0

Neutral주식등의대량보유상황보고서(일반)2026-10-19
Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-19
Neutral자산재평가결과(자율공시)2026-10-06
Neutral임시주주총회결과2026-10-02
Neutral[기재정정]자산재평가실시결정(자율공시)2026-10-02